Report
EUR 236.14 For Business Accounts Only

Q2 figures, a big smile

The H1 sales grew up 5%, yoy, to AED799.5M, pulled up by a 9% Q2 revenue increase. The operating profit jumped from AED115.8M to AED131.4M thanks to the improving gross margin and to the decreasing direct costs, up 1.6%. The net profit won 10% to establish at AED131.5M. The gross debts increased from AED703.3M, as of December, 2014, to AED887.3M as of June, 2015.
Underlying
Gulf Pharmaceutical Industries

Provider
AlphaMena Corporate Services
AlphaMena Corporate Services

AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.

Other Reports on these Companies
Other Reports from AlphaMena Corporate Services

ResearchPool Subscriptions

Get the most out of your insights

Get in touch